PerkinElmer Q2 Revenues Up 2 Percent; Discloses Bioo Scientific Acquisition | GenomeWeb

This article has been updated to include a downgrade note from Mizuho Securities.

NEW YORK (GenomeWeb) – PerkinElmer reported after the close of the market on Thursday that its second quarter revenues rose 2 percent year over year thanks to a 4 percent increase in its human health business which offset a 1 percent dip in environmental health revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.